Dark

Check out our API

CLSN
Celsion Corporation
stock NASDAQ

Inactive

Sep 20, 2022

1.96USD0.000%(0.00)67,986

Pre-market

0.00USD-100.000%(-1.96)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

08:11AM EST Celsion Corp Highlights In-Process Vaccine Candidate Benzinga

08:00AM EST Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants GlobeNewswire Inc

Jan 13, 2022

05:30PM EST Celsion Corporation Announces Pricing of $30 Million Registered GlobeNewswire Inc

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Jan 10, 2022

08:45PM EST Celsion Corporation Announces Pricing of $30 Million Registered GlobeNewswire Inc

Nov 29, 2021

08:33AM EST Celsion CorporationTo Present Poster At Cytokine-Based Cancer Immunotherapies Summit Dec. 2 Benzinga

08:30AM EST Celsion CorporationsGEN-1 IL-12 Program in Advanced Ovarian Cancer to be Featuredin Poster Presentation GlobeNewswire Inc

Nov 22, 2021

07:31AM EST CLSN: OVATION 2 Trial Nears 70% of Target Enrollment Benzinga

Nov 17, 2021

12:06PM EST Watching Celsion Shares; Zacks Small-Cap Research Sets $3.50 Valuation Benzinga

Nov 15, 2021

11:09AM EST Celsion Q3 EPS $(0.06) Beats $(0.08) Estimate Benzinga

11:07AM EST Earnings Scheduled For November 15, 2021 Benzinga

08:30AM EST Balance Sheet Supports Focus onImmuno-Oncology andNext-Generation Vaccine Initiative GlobeNewswire Inc

Nov 9, 2021

09:00AM EST Celsion Corporation to Hold Third Quarter 2021 Financial Results GlobeNewswire Inc

Nov 8, 2021

09:17AM EST Celsion Announces Its Application To Sell $1.5M Of New Jersey Net Operating Losses Has Been Approved By NJEDA's Board Of Directors Benzinga

09:00AM EST Application Approval Will Further Extend Current Operating Runway to Over Three Years GlobeNewswire Inc

08:30AM EST Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions GlobeNewswire Inc

Oct 19, 2021

06:03AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.50 A.M. EDT). RTTNews

Oct 16, 2021

07:21AM EDT CLSN: Initiating Coverage of Celsion Corporation; Novel DNA-Based Cancer Immunotherapy Technology Benzinga

Oct 15, 2021

09:02AM EDT Celsion Reports Will Give Oral Presentation At Int'l. Vaccine Congress Monday, Oct. 18 At 7:30 a.m. EDT Benzinga

09:00AM EDT Chief Science Officer Dr. Khursheed Anwer to Deliver VirtualPresentation Monday, October 18 at 7:30 a.m. Eastern Time GlobeNewswire Inc

Oct 12, 2021

09:20AM EDT Celsion Corporation Announces Oral Presentation At International Vaccines Congress Benzinga

09:00AM EDT Chief Science Officer Dr. Khursheed Anwer to Deliver VirtualPresentation on Celsions Ongoing Work with DNA-based Vaccines GlobeNewswire Inc

Oct 11, 2021

09:02AM EDT Celsion GmbH Announces Publication Of Article Reviewing History Of ThermoDox Drug Development In Advanced Drug Delivery Reviews Benzinga

09:00AM EDT Investigator-Sponsored Research with ThermoDoxContinues in Multiple Indications GlobeNewswire Inc

Oct 5, 2021

09:01AM EDT Celsion Corporation Announces New Management Appointments Benzinga

09:00AM EDT Celsion Corporation Adds Key Resources to its Vaccine Development GlobeNewswire Inc

Sep 30, 2021

09:00AM EDT Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investment conferences in October: GlobeNewswire Inc

Sep 17, 2021

09:00AM EDT Celsion, Hainan Poly Pharm Sign Agreement To Manufacture Celsion's DNA-Based Vaccine; Terms Not Disclosed Benzinga

09:00AM EDT Expands GEN-1 Program Collaboration to AddClinical and Commercial Batches of Investigational Vaccine GlobeNewswire Inc

Sep 2, 2021

08:09AM EDT Celsion Reports T-cell, B-cell Response From In Vivo Studios With Its PLACCINE DNA Vaccine Platform Benzinga

08:00AM EDT Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 GlobeNewswire Inc

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

08:09AM EDT Celsion Q2 EPS $(0.06) Up From $(0.18) YoY, Sales $125.00K, Same YoY Benzinga

08:00AM EDT Strong Balance Sheet Supports Focus inImmuno-Oncology and onNext-Generation Vaccine InitiativeConference Call Begins Todayat 11:00 a.m. Eastern Time GlobeNewswire Inc

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 29, 2021

10:04AM EDT UPDATE: Celsion Says 'Data show dose-dependent suppression of immune-suppressive agents' Benzinga

10:01AM EDT Celsion Highlights Results From OVATION 1 Study With GEN-1 In Patients With Advanced Ovarian Cancer Published In Journal Of Clinical Cancer Research Benzinga

Jul 19, 2021

08:07AM EDT Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients In The Phase II Portion Of The OVATION 2 Study With GEN-1 In Advanced Ovarian Cancer Benzinga

08:00AM EDT OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted GlobeNewswire Inc

Jul 15, 2021

08:00AM EDT VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 GlobeNewswire Inc

Jul 1, 2021

08:15AM EDT Celsion Reports Commencement Of Enrollment In Oxford University's Phase 1 Study With Its ThermoDox, Focused Ultrasound In Pancreatic Cancer Benzinga

08:00AM EDT Celsion GmbH Announces Commencement of Enrollment in Oxford GlobeNewswire Inc

Jun 23, 2021

08:13AM EDT Celsion Says Establishes Wholly Owned Subsidiary To Manage Investigator-Sponsored Development Of ThermoDox Benzinga

08:00AM EDT Celsion GmbHwill manage current and future cancer studies with ThermoDox GlobeNewswire Inc

Jun 21, 2021

08:14AM EDT Celsion Corporation Enters $10 Mln Strategic Loan Facility With Silicon Valley Bank RTTNews

08:09AM EDT Celsion Corporation Enters into $10M Strategic Loan Facility with Silicon Valley Bank Benzinga

08:00AM EDT Celsion Corporation Enters into $10 Million Strategic Loan GlobeNewswire Inc

Jun 9, 2021

08:10AM EDT Celsion Appoints Christine Pellizzari To Board RTTNews

08:00AM EDT Celsion Appoints Christine A. Pellizzari to its Board of Directors GlobeNewswire Inc

Jun 8, 2021

08:13AM EDT Celsion Appoints Stacy Lindborg To Its Board RTTNews

08:00AM EDT 25-year pharmaceutical industry executive brings broad drug development perspective GlobeNewswire Inc

Jun 7, 2021

05:00PM EDT A Quorum Has Been Achieved to Reconvene Annual Meeting on Thursday June 10, 2021 GlobeNewswire Inc

Jun 4, 2021

10:12AM EDT 49% of Shares Voted, Quorum Not EstablishedTo Hold Annual Meeting GlobeNewswire Inc

Jun 2, 2021

08:00AM EDT Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met GlobeNewswire Inc

May 14, 2021

08:50AM EDT Celsion Q1 EPS $(0.09) Up From $(0.20) YoY, Sales $125.00K, Same YoY Benzinga

08:00AM EDT Focus on Immuno-Oncology andNext-Generation Vaccines is Supported with a Strong Balance Sheet GlobeNewswire Inc

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

04:03AM EDT Earnings Scheduled For May 14, 2021 Benzinga

May 11, 2021

08:10AM EDT Celsion Receives $1.85M From Sale of Its New Jersey State Net Operating Losses Benzinga

08:00AM EDT Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 GlobeNewswire Inc

May 7, 2021

08:30AM EDT Celsion Corporation to Hold First Quarter 2021 Financial Results GlobeNewswire Inc

Apr 22, 2021

08:30AM EDT Celsion Management Participates in Alliance Global Partners GlobeNewswire Inc

Apr 5, 2021

05:00PM EDT Celsion Corporation (NASDAQ: CLSN) (Celsion or the Company), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net proceeds of $13.9 million, after deducting placement agents' fees but before expenses payable by the Company. GlobeNewswire Inc

Apr 1, 2021

09:37AM EDT Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates Benzinga

08:36AM EDT Celsion Says Poster On Co's Phase I/II OVATION 2 Study Presented At Society Of Gynecologic Oncology Virtual Annual Meeting On Women's Canver Benzinga

08:30AM EDT Company reports further strengthening of R0 resection results in patients treated with GEN-1 GlobeNewswire Inc

Mar 31, 2021

08:08AM EDT Celsion Announces $15M Offering Of ~11.5M Shares Benzinga

08:00AM EDT CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING GlobeNewswire Inc

Mar 19, 2021

09:24AM EDT Celsion Corp. (CLSN) reported a net loss of $21.5 million or $0.67 per share in 2020, compared to a loss of $16.8 million or $0.77 per share, prior year. Research and development expenses were $11.3 million in 2020, a decrease of 15% from prior year. RTTNews

09:09AM EDT Celsion 2020 Net Loss $21.5 Mln Or $0.67/Shr Vs Loss $16.8 Mln Or $0.77/Shr Last Year RTTNews

08:46AM EDT Celsion FY 2020 EPS $(0.67) Vs $(0.77) YoY Benzinga

08:45AM EDT Entered 2021 with a Focus on Cancer Immunotherapy andNext-Generation Infectious Vaccines and a Strong Balance Sheet GlobeNewswire Inc

07:46AM EDT The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs Benzinga

04:08AM EDT Earnings Scheduled For March 19, 2021 Benzinga

Mar 12, 2021

08:45AM EST Celsion Corporation to Hold Year-End 2020 Financial Results and GlobeNewswire Inc

Mar 2, 2021

08:56AM EST Celsion Corp Says Poster On Co's Phase I/II OVATION 2 Study To Be Presented At Society Of Gynecology Oncology Virtual Annual Meeting On Women's Cancer Benzinga

08:45AM EST Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster on the Companys Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has been accepted for presentation at the Virtual Annual Meeting on Womens Cancer, sponsored by the Society of Gynecologic Oncology. GlobeNewswire Inc

Feb 26, 2021

08:45AM EST Celsion Corporation to Participate in the Virtual GlobeNewswire Inc

Feb 25, 2021

11:34AM EST Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm Benzinga

09:19AM EST Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores Benzinga

08:45AM EST Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement GlobeNewswire Inc

Feb 23, 2021

08:03AM EST Celsion Says Receives $2M Allocation Through New Jersey Technology Business Certificate Transfer Program Benzinga

08:00AM EST Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years GlobeNewswire Inc

Feb 22, 2021

02:51PM EST Mid-Afternoon Market Update: Dow Jumps Over 100 Points; Cooper Tire Shares Jump Benzinga

12:11PM EST Mid-Day Market Update: Nasdaq Tumbles 250 Points; Celsion Shares Spike Higher Benzinga

07:31AM EST Celsion Corporation Receives FDA Fast Track Designation For GEN-1 In Advanced Ovarian Cancer Benzinga

07:30AM EST Celsions Commitment to Promoting Immune System Solutions to Fight Life-Threatening DiseasesGranted an Accelerated Development Pathway GlobeNewswire Inc

Feb 12, 2021

08:31AM EST Celsion Corporation Announces Formation Of Vaccine Advisory Board Benzinga

08:30AM EST Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 GlobeNewswire Inc

Feb 11, 2021

08:30AM EST Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study, and Phase III OPTIMA Study Conclusions GlobeNewswire Inc

Feb 3, 2021

05:18PM EST Celsion Has Regained Compliance With The Minimum Bid Price Listing Requirement Under Nasdaq Rule Benzinga

Feb 1, 2021

03:20PM EST Celsion 13G Filing From Ayrton Capital Shows 8.95% Stake In Co. Benzinga

Jan 28, 2021

08:00AM EST The PLACCINE Platform Technology is Conceived to Enable Rapid Development of Vaccines That Can Address a Broad Range of Infectious Agents, including SARS-Associated Coronavirus (SARS-CoV) GlobeNewswire Inc

Jan 27, 2021

05:29AM EST Pre-market Movers In Healthcare Sector: TMBR, AEZS, SRNE, RTTNews

Jan 26, 2021

05:00PM EST CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED GlobeNewswire Inc

Jan 22, 2021

08:41AM EST Celsion Corporation Announces $35M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Benzinga

08:40AM EST CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT GlobeNewswire Inc

Jan 21, 2021

02:46PM EST Mid-Afternoon Market Update: Dow Rises 50 Points; Vinco Ventures Shares Spike Higher Benzinga

10:01AM EST Looking Into Celsion's Return On Capital Employed Benzinga

08:27AM EST UPDATE: Celsion Says From Sept. 8, 2020 Through Termination Date, Sold 2.8M Common Shares Under 2020 Purchase Agreement Generating Proceeds Of $2.2M Benzinga

Dec 29, 2020

09:10AM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. GlobeNewswire Inc

Dec 28, 2020

12:56PM EST Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

Dec 26, 2020

09:00AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 24, 2020

11:00AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Celsion Corporation investors under the federal securities laws. GlobeNewswire Inc

Dec 22, 2020

05:02PM EST Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN PR Newswire

Dec 18, 2020

11:50AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 16, 2020

05:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Dec 15, 2020

12:27PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Celsion Corporation investors under the federal securities laws. GlobeNewswire Inc

Dec 13, 2020

12:40AM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Dec 12, 2020

10:00AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 10, 2020

04:20PM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. GlobeNewswire Inc

Dec 9, 2020

05:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Dec 8, 2020

12:16PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Celsion Corporation investors under the federal securities laws. GlobeNewswire Inc

Dec 7, 2020

11:55PM EST Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN PR Newswire

09:15PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Dec 3, 2020

05:17PM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. GlobeNewswire Inc

11:30AM EST Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period). GlobeNewswire Inc

04:00AM EST Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline - CLSN PR Newswire

Dec 2, 2020

07:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Nov 30, 2020

10:47PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Nov 26, 2020

10:00AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period). GlobeNewswire Inc

12:01AM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Nov 25, 2020

06:30PM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. GlobeNewswire Inc

Nov 24, 2020

07:00PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Celsion Corporation investors under the federal securities laws. GlobeNewswire Inc

07:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Nov 22, 2020

02:09AM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Nov 20, 2020

06:00PM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. GlobeNewswire Inc

Nov 19, 2020

11:00AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period). GlobeNewswire Inc

Nov 18, 2020

08:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Nov 16, 2020

10:02PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

08:45AM EST Celsion: Q3 Earnings Insights Benzinga

08:33AM EST Celsion Q3 Adj. EPS $(0.17) Misses $(0.13) Estimate, Sales $125.00K Beat $80.00K Estimate Benzinga

08:30AM EST Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer GlobeNewswire Inc

04:26AM EST Earnings Scheduled For November 16, 2020 Benzinga

Nov 13, 2020

02:46PM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. GlobeNewswire Inc

11:00AM EST CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020 Business Wire

Nov 12, 2020

03:38PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Celsion Corporation investors under the federal securities laws. GlobeNewswire Inc

Nov 11, 2020

08:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

04:41PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

02:36PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the Class Period). GlobeNewswire Inc

11:00AM EST CLSN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies GlobeNewswire Inc

Nov 9, 2020

07:30PM EST Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN PR Newswire

08:30AM EST Celsion Corporation to Hold Third Quarter 2020 Financial Results GlobeNewswire Inc

Nov 7, 2020

05:23PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Nov 3, 2020

07:49PM EST Class Action Lawsuit Against Celsion Corporation; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN PR Newswire

12:57PM EST Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that: GlobeNewswire Inc

11:01AM EST Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020 PR Newswire

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Nov 2, 2020

09:10AM EST Stocks Trading Near 52-Week Lows Before Open On Monday, Nov. 2, 2020: CLSN, MRTN, UTSI, LXRX, TTNP, ORTX, ARTL, PEI, CBL Benzinga

Oct 30, 2020

10:15PM EDT /C O R R E C T I O N -- Pomerantz LLP/ PR Newswire

01:30AM EDT Pomerantz Law Firm Announces the Filing of a Class Action against Celsion PR Newswire

Oct 12, 2020

08:06AM EDT Celsion Corporation Issues Letter To Stockholders Benzinga

08:00AM EDT CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox Investigator-Sponsored Studies GlobeNewswire Inc

Oct 7, 2020

04:15PM EDT Horizon Technology Finance Provides Third Quarter 2020 Portfolio Update PR Newswire

Sep 8, 2020

08:35AM EDT Celsion Announces Common Stock Purchase Agreement with Lincoln GlobeNewswire Inc

08:29AM EDT Celsion Files For Sale Of Up To $26M Shares That Co. May Sell To Lincoln Park Capital Fund Or Lincoln Park Benzinga

Sep 2, 2020

08:07AM EDT Celsion Corporation Restructures Strategic Loan Facility Benzinga

08:00AM EDT Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsions Capitalization GlobeNewswire Inc

Aug 14, 2020

08:48AM EDT Celsion: Q2 Earnings Insights Benzinga

08:09AM EDT Celsion Q2 Loss/Shr $0.18 Vs Loss $0.29 Last Year RTTNews

08:04AM EDT Celsion Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $125.00K Beat $80.00K Estimate Benzinga

08:00AM EDT Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer GlobeNewswire Inc

Aug 7, 2020

08:30AM EDT Celsion Corporation to Hold Second Quarter 2020 Financial Results GlobeNewswire Inc

Aug 4, 2020

08:36AM EDT Celsion Corporation To Continue Following Patients In Phase III OPTIMA Study For Overall Survival Benzinga

08:30AM EDT Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue GlobeNewswire Inc

Jul 27, 2020

08:30AM EDT Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients GlobeNewswire Inc

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Jul 16, 2020

06:34AM EDT Oppenheimer Downgrades Celsion to Perform Benzinga

Jul 15, 2020

11:15AM EDT Celsion Shares Move Lower; Hearing Co. Hosting Conference Call Benzinga

Jul 14, 2020

08:30AM EDT Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its current observations about the results of the OPTIMA Study and the Companys next steps. GlobeNewswire Inc

05:11AM EDT 80 Biggest Movers From Yesterday Benzinga

Jul 13, 2020

02:31PM EDT Mid-Afternoon Market Update: Dow Jumps 400 Points; Equillium Shares Spike Higher Benzinga

12:01PM EDT Mid-Day Market Update: Benefytt Technologies Surges Following Acquisition News; NextCure Shares Slide Benzinga

10:13AM EDT Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Estimates Benzinga

08:41AM EDT Celsion Receives Recommendation From Independent DMC To Consider Stopping Phase III OPTIMA Study RTTNews

08:41AM EDT Celsion Shares Previously Halted On News Pending, To Resume Trading At 9 a.m. EDT; Company Just Reported They Received Recommendation To Consider Stopping Phase 3 OPTIMA Study Benzinga

08:33AM EDT Celsion Corporation Receives Recommendation From Independent Data Monitoring Committee To Consider Stopping Phase 3 OPTIMA Study Benzinga

08:30AM EDT Recommendation Based on DMCs Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival GlobeNewswire Inc

Share